+
   
* Taking on stereotype threat in the classroom
   
* Leaders in public affairs, social advocacy receive high honor from CU
   
* Staff Council hears details on possible changes to tuition benefit
   
* University's mainframe computer facing retirement
   
* Work of Boulder art faculty showcased at new museum
   
* CU-Boulder names four finalists for Law School dean
   
* Five questions for Dennis Roop
   
* Conference examining how students learn
   
* What matters? Conference on World Affairs will talk it over
   
* People
   
* Did you know...
   
* Letters to the editor
 
 NEWS FROM THE CU SYSTEM
 
  CU-BOULDER
  Chef, dietitian serving nutrition tips at UMC
 
  UCCS
  Campus posts 3 percent enrollment growth
 
  CU DENVER
  Gift from Walmart to help greening of Colorado communities
 
  ANSCHUTZ MEDICAL CAMPUS
  University of Colorado Hospital getting 'Healthy for Good'
 
  CU FOUNDATION
  CU-Boulder Parent Leadership Society members raise bar for giving
 
  TECH TRANSFER
  CU licensee acquired by Alexion Pharma in buyout
 
Download Newsleter in PDF
 

Home
Newsletter Archive
Letters to the Editor
Contact Us

   
   
   
   
   
   
   
   
   
   
   

News from the CU system - Tech Transfer

CU licensee acquired by Alexion Pharma in buyout

Taligen Therapeutics, a licensee of the University of Colorado, was acquired recently by Cheshire, Conn.-based Alexion Pharmaceuticals for $111 million and contingent payments. Taligen, headquartered in Cambridge, Mass., has been focused on the discovery and development of novel protein therapeutics.

Taligen's portfolio includes monoclonal antibodies and recombinant fusion proteins that target key factors in the alternative pathway of the complement system, which Taligen's founders – including CU Professor V. Michael Holers, M.D., of the University of Colorado School of Medicine – have validated as an important amplification loop in the inflammation process. Former Taligen CEO Abbie Celniker, Ph.D., will head up Alexion's new Translational Medicine Group, which will accelerate development of Taligen's pre-clinical product candidates.

Taligen was founded in March 2004 and was a recipient of CU's first round of proof-of-concept investments in 2005. In 2008, Taligen received the University of Colorado Technology Transfer Office bioscience company of the year award. The company's most recent funding was a Series B funding round lead by Clarus Ventures, Alta Partners, Sanderling Ventures and Colorado-based High Country Venture.

 

Bookmark - Print - Share

 
Previous Tech Transfer Stories

02/02/2011
Biopharmaceutical company signs license agreement with CU

01/19/2011
Researchers, business leaders honored at annual awards ceremony

10/27/2010
Boulder firm signs research, licensing agreements with CU for heart study

10/13/2010
Symposium to showcase CU's research enterprise

09/29/2010
Anti-cancer compounds licensed from CU

09/22/2010
Aurora company licenses CU technology for brain disease treatment

09/15/2010
Boulder company to commercialize CU hybrid aircraft propulsion technology

07/14/2010
Aurora company licenses unusual approach to treating inflammatory disease

06/30/2010
Optioned device helps diagnose acid reflux, other esophageal diseases

06/16/2010
Taste Connections licenses CU low-protein meat supplement

05/26/2010
White House turns to CU for input on technology commercialization

05/05/2010
Biotech company expands Alzheimer's disease partnership with CU

04/21/2010
Sanofi Pasteur licenses E. coli vaccine technology

04/07/2010
CU ranked 14th among universities in 'Patent Power'

03/31/2010
CU cardiovascular monitoring technology to be commercialized

03/10/2010
Israel-based company licenses water desalination technology

03/03/2010
Colorado company licenses CU test to assess chronic liver disease

01/20/2010
AgriHouse completes license for CU water management technology

01/13/2010
AmideBio licenses technology from CU

01/06/2009
Business collaboration leads to high ranking for CU-Boulder

12/16/2009
License agreement gives Viral Genetics Inc. right to develop cancer therapies

12/09/2009
Soligenix options CU vaccine technology

12/02/2009
Aurora company licenses CU technology for 3-D heart modeling

09/23/2009
Colorado firm aims to commercialize CU breakthroughs in pain management

09/16/2009
Office reports best year for invention disclosures

09/16/2009
Office invites bioscience faculty to submit grant proposals

09/02/2009
Reading software based on CU technology draws national attention

08/19/2009
CU startup to develop 'biogenerator' for medical devices

08/06/2009
CU startup licenses social networking iPhone app

Click for University Relations Web Site E-mail: newsletter@cu.edu